全文获取类型
收费全文 | 330篇 |
免费 | 22篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 2篇 |
妇产科学 | 14篇 |
基础医学 | 35篇 |
口腔科学 | 1篇 |
临床医学 | 19篇 |
内科学 | 87篇 |
皮肤病学 | 10篇 |
神经病学 | 9篇 |
特种医学 | 6篇 |
外科学 | 37篇 |
综合类 | 1篇 |
预防医学 | 26篇 |
药学 | 17篇 |
肿瘤学 | 88篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 1篇 |
2019年 | 2篇 |
2018年 | 1篇 |
2016年 | 1篇 |
2015年 | 8篇 |
2014年 | 6篇 |
2013年 | 11篇 |
2012年 | 18篇 |
2011年 | 15篇 |
2010年 | 10篇 |
2009年 | 2篇 |
2008年 | 8篇 |
2007年 | 14篇 |
2006年 | 18篇 |
2005年 | 17篇 |
2004年 | 12篇 |
2003年 | 15篇 |
2002年 | 11篇 |
2001年 | 22篇 |
2000年 | 15篇 |
1999年 | 19篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1996年 | 8篇 |
1995年 | 8篇 |
1994年 | 1篇 |
1993年 | 2篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 2篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 12篇 |
1986年 | 6篇 |
1985年 | 13篇 |
1984年 | 10篇 |
1983年 | 4篇 |
1982年 | 2篇 |
1979年 | 3篇 |
1977年 | 3篇 |
1975年 | 1篇 |
1972年 | 1篇 |
1970年 | 2篇 |
1969年 | 1篇 |
1966年 | 1篇 |
1965年 | 1篇 |
1941年 | 1篇 |
排序方式: 共有353条查询结果,搜索用时 0 毫秒
1.
3-Alkoxy-1.2.3-oxathiazolidin-4-one-2-oxides and 1-Alkoxyindolin-2-ones from N-Alkoxyglycolamides and Thionyl Chloride or 1.1′-Thionyldiimidazole The reaction of N-alkoxyglycolamides 1 with thionyl chloride or 1.1′-thionyldiimidazole is shown to produce, dependending on the substituents at C-2 in 1 , either 3-alkoxy-1.2.3-oxathiazolidin-4-one-2-oxides 4 or 1-alkoxy-3-arylindolin-2-ones 6 . 相似文献
2.
Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. 总被引:2,自引:0,他引:2
下载免费PDF全文
![点击此处可从《Clinical and experimental immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
M Heike U Mbius A Knuth S Meuer K H Meyer zum Büschenfelde 《Clinical and experimental immunology》1988,74(3):431-434
The recently described Ta1 antigen is expressed by activated T cells in vitro and in vivo, as observed in patients with certain immune-mediated diseases, such as multiple sclerosis. In this paper we report on the tissue distribution of the Ta1 antigen. Serological testing of human tumour cell lines and immunohistochemical analysis of human tissue sections revealed a reactivity of the anti-Ta1 antibody with normal and malignant tissues of the upper gastro-intestinal tract, the biliary tract, exocrine pancreas and kidney. SDS-PAGE analysis of immunoprecipitates from 125I-labelled cells, employing the anti-Ta1 antibody, yielded a 113-115 kD band from three serologically Ta1 positive tumour cell lines, from a serologically Ta1 negative human EBV-transformed B lymphoblastoid cell line, from peripheral blood mononuclear cells (PBMC) and, as previously described, a 105 kD band from PHA activated T cells (Fox et al., 1984). After endoglycosidase F treatment similar bands of 85 kD were precipitated from activated T cells and from tumour cell lines. It is therefore likely that very similar glycoproteins, which differ only modestly in the size of carbohydrate chains, bear the Ta1 epitope on Ta1 positive tissues. 相似文献
3.
S C Meuer A Knuth H Lerch K H Meyer zum Büschenfelde H P Dienes 《The New England journal of medicine》1986,315(4):264-265
4.
Bu HZ Magis L Knuth K Teitelbaum P 《Journal of chromatography. B, Biomedical sciences and applications》2001,753(2):321-326
A highly efficient direct injection/on-line guard cartridge extraction-tandem mass spectrometry (DI/GCE-MS-MS) method has been validated for high-throughput evaluation of cytochrome P450 (CYP) 2D6 inhibition potential using human hepatic microsomes and 96-well microtiter plates. Microsomal incubations were terminated with formic acid, centrifuged, and the resulting supernatants were injected for DI/GCE-MS-MS analysis. Due to the novel use of an extremely short C18 guard cartridge, this method exhibits several advantages, such as no sample preparation, excellent on-line extraction, short run time (2.5 min), and minimized source contamination and performance deterioration. The DI/GCE-MS-MS method demonstrates acceptable accuracy and precision for the quantification of dextrorphan, a marker metabolite of dextromethorphan mediated by CYP2D6, in microsomal incubations. The CYP2D6 inhibition assay has been validated using quinidine as a known selective inhibitor of the isoform. The IC50 value (0.20 microM) measured by the new method is in good agreement with the literature value (0.22 microM). 相似文献
5.
Atanackovic D Matsuo M Ritter E Mazzara G Ritter G Jäger E Knuth A Old LJ Gnjatic S 《Journal of immunological methods》2003,278(1-2):57-66
CD4+ T cells play an important role in the induction and maintenance of an effective antiviral and antitumor immune response. However, standardized monitoring of antigen-specific CD4+ T cells has not been established at the single-cell level. We now present a sensitive, specific, and simple methodology in which purified memory CD4+ T cells are expanded from PBMC in a single cycle of antigen-driven stimulation and quantitatively assayed by interferon-gamma ELISPOT. Issues of nonspecific background in assays were resolved with the use of innovative target cells, autologous PHA-expanded CD4+ T cells (T-APC). Remarkably, T-APC could not only present peptide epitopes from model antigens NY-ESO-1 and influenza nucleoprotein, but could also process full-length antigen endogenously expressed from recombinant fowlpox vector. This approach makes it possible to monitor CD4+ T cells in large series of patients, regardless of HLA haplotype, against the full peptide repertoire of a given antigen. 相似文献
6.
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses 总被引:40,自引:0,他引:40
下载免费PDF全文
![点击此处可从《Proceedings of the National Academy of Sciences of the United States of America》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Jäger E Nagata Y Gnjatic S Wada H Stockert E Karbach J Dunbar PR Lee SY Jungbluth A Jäger D Arand M Ritter G Cerundolo V Dupont B Chen YT Old LJ Knuth A 《Proceedings of the National Academy of Sciences of the United States of America》2000,97(9):4760-4765
NY-ESO-1, a member of the cancer-testis family of antigens, is expressed in a subset of a broad range of different human tumor types. Patients with advanced NY-ESO-1-expressing tumors frequently develop humoral immunity to NY-ESO-1, and three HLA A2-restricted peptides were defined previously as targets for cytotoxic CD8(+) T cells in a melanoma patient with NY-ESO-1 antibody. The objectives of the present study were (i) to develop enzyme-linked immunospot (ELISPOT) and tetramer assays to measure CD8(+) T cell responses to NY-ESO-1, (ii) to determine the frequency of CD8(+) T cell responses to NY-ESO-1 in a series of HLA-A2 patients with NY-ESO-1 expressing tumors, (iii) to determine the relation between CD8(+) T cell and humoral immune responses to NY-ESO-1, and (iv) to compare results of NY-ESO-1 ELISPOT assays performed independently in two laboratories with T cells from the same patients. NY-ESO-1 ELISPOT and tetramer assays with excellent sensitivity, specificity, and reproducibility have been developed and found to correlate with cytotoxicity assays. CD8(+) T cell responses to HLA-A2-restricted NY-ESO-1 peptides were detected in 10 of 11 patients with NY-ESO-1 antibody, but not in patients lacking antibody or in patients with NY-ESO-1-negative tumors. The results of ELISPOT assays were concordant in the two laboratories, providing the basis for standardized monitoring of T cell responses in patients receiving NY-ESO-1 vaccines. 相似文献
7.
8.
9.
10.
Dirk R. Bulian Linda Trump Jürgen Knuth Nicola Cerasani Markus M. Heiss 《Langenbeck's archives of surgery / Deutsche Gesellschaft fur Chirurgie》2013,398(4):571-579